NCT04728139

Brief Summary

  • Evaluation Of Glypican 3 in serum of colorectal cancer patients .
  • Correlation between Glypican 3 and clinicopathological characteristics of colorectal cancer .

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P25-P50 for not_applicable colorectal-cancer

Timeline
Completed

Started Mar 2022

Typical duration for not_applicable colorectal-cancer

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 13, 2020

Completed
5 months until next milestone

First Posted

Study publicly available on registry

January 28, 2021

Completed
1.1 years until next milestone

Study Start

First participant enrolled

March 1, 2022

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

January 13, 2022

Status Verified

January 1, 2022

Enrollment Period

2.5 years

First QC Date

September 13, 2020

Last Update Submit

January 11, 2022

Conditions

Colorectal Cancer

Keywords

glypican 3

Outcome Measures

Primary Outcomes (1)

  • Evaluation of Glypican 3 role as a predictive and diagnostic marker of colorectal marker .

    measurment of GLYPICAN 3 level in serum of colorectal patients using ELISA method

    3 years

Secondary Outcomes (1)

  • Addition of Glypican 3 to the routine markers of colorectal cancer . - Correlatin of this marker with the disease pathology and management procedures .

    3 years

Study Arms (2)

patients with colorecta cancer

ACTIVE COMPARATOR
Diagnostic Test: glypican 3

healthy individuals

NO INTERVENTION

Interventions

glypican 3DIAGNOSTIC_TEST

Assessment of glypican 3 presence in colorectal cancer patients using ELISA

patients with colorecta cancer

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with colorectal cancer and admitted to south egypt cancer institute .

You may not qualify if:

  • Other malignant diseases .
  • Patients received chemotherapy for colorectal cancer .

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (13)

  • Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010 Jun;138(6):2101-2114.e5. doi: 10.1053/j.gastro.2010.01.058.

    PMID: 20420949BACKGROUND

  • Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971. Epub 2014 Sep 21.

    PMID: 25328522BACKGROUND

  • Ijaz B, Formentin E, Ronci B, Locato V, Barizza E, Hyder MZ, Lo Schiavo F, Yasmin T. Salt tolerance in indica rice cell cultures depends on a fine tuning of ROS signalling and homeostasis. PLoS One. 2019 Apr 30;14(4):e0213986. doi: 10.1371/journal.pone.0213986. eCollection 2019.

    PMID: 31039145BACKGROUND

  • Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001 Aug;108(4):497-501. doi: 10.1172/JCI13712. No abstract available.

    PMID: 11518720BACKGROUND

  • Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009 Mar;34(3):649-56. doi: 10.3892/ijo_00000190.

    PMID: 19212669BACKGROUND

  • Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011 Jul 1;3(7):a004952. doi: 10.1101/cshperspect.a004952.

    PMID: 21690215BACKGROUND

  • Fico A, Maina F, Dono R. Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci. 2011 Mar;68(6):923-9. doi: 10.1007/s00018-007-7471-6. Epub 2011 Feb 22.

    PMID: 18087675BACKGROUND

  • Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001 Jul 15;61(14):5562-9.

    PMID: 11454708BACKGROUND

  • Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res. 2004 Aug 1;10(15):5178-86. doi: 10.1158/1078-0432.CCR-03-0103.

    PMID: 15297422BACKGROUND

  • Bosse KR, Raman P, Zhu Z, Lane M, Martinez D, Heitzeneder S, Rathi KS, Kendsersky NM, Randall M, Donovan L, Morrissy S, Sussman RT, Zhelev DV, Feng Y, Wang Y, Hwang J, Lopez G, Harenza JL, Wei JS, Pawel B, Bhatti T, Santi M, Ganguly A, Khan J, Marra MA, Taylor MD, Dimitrov DS, Mackall CL, Maris JM. Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell. 2017 Sep 11;32(3):295-309.e12. doi: 10.1016/j.ccell.2017.08.003.

    PMID: 28898695BACKGROUND

  • Aleksikova RIa. [On the morbidity of school-children in senior classes of Leningrad boarding schools]. Zdravookhr Ross Fed. 1965 Nov;9(11):11-3. No abstract available. Russian.

    PMID: 4225756BACKGROUND

  • Chan ES, Pawel BR, Corao DA, Venneti S, Russo P, Santi M, Sullivan LM. Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases. Pediatr Dev Pathol. 2013 Jul-Aug;16(4):272-7. doi: 10.2350/12-06-1216-OA.1. Epub 2013 Mar 26.

    PMID: 23530909BACKGROUND

  • Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, Ohno A, Kondo K, Kataoka H. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015 Oct 1;137(7):1643-51. doi: 10.1002/ijc.29518. Epub 2015 Apr 6.

    PMID: 25784484BACKGROUND

MeSH Terms

Conditions

Colorectal NeoplasmsSimpson-Golabi-Behmel syndrome

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Central Study Contacts

Reham Hany Mohammed

CONTACT

01118441744rehamhany809@gmail.com

Hosney Badrawy Hamed

CONTACT

01060664976BadranH@yahoo.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
residet doctor

Study Record Dates

First Submitted

September 13, 2020

First Posted

January 28, 2021

Study Start

March 1, 2022

Primary Completion

September 1, 2024

Study Completion

October 1, 2024

Last Updated

January 13, 2022

Record last verified: 2022-01